Metyrapone/oxazepam - Embera

Drug Profile

Metyrapone/oxazepam - Embera

Alternative Names: EMB 001C; EMB-001

Latest Information Update: 24 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Louisiana State University
  • Developer Embera NeuroTherapeutics
  • Class Antidepressants; Antihormones; Anxiolytics; Benzodiazepinones; Pyridines
  • Mechanism of Action GABA A receptor agonists; Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cocaine abuse

Highest Development Phases

  • Phase I Cocaine abuse; Smoking withdrawal

Most Recent Events

  • 08 May 2017 Adverse events and pharmacokinetics data from a phase Ib trial in Cocaine abuse released by Embera NeuroTherapeutics
  • 08 May 2017 Embera NeuroTherapeutics plans a phase II trial for Smoking withdrawal
  • 08 May 2017 Embera NeuroTherapeutics and the National Institute on Drug Abuse complete a phase I trial in Cocaine abuse in USA (NCT02856854)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top